Pipeline
TEC-001
TEC-001 with transarterial embolization (TATE) uses a well-established procedure to shut off blood supply to the tumor to create the hypoxic environment necessary for drug activation. TATE has the potential to enhance the efficacy of FDA-approved immune checkpoint inhibitors (ICIs) and transform the standard of care for patients battling cancer. TEC-001 works with ICIs to generate a systemic anticancer immune response that can target cancer cells throughout the body. This durable anticancer immunity helps safeguard against future cancer growth and promote lasting remission.
TEC-002
Our second pipeline, TEC-002 induces tumor death and presents tumor antigen to the immune system. This process activates the body's immune system, enabling it to recognize tumors as foreign substances and generate an immune response against them. TEC-002 is designed for use with all solid tumors and is anticipated to have broad applications.
TEC-003
Our third pipeline, TEC-003, is triggered after TEC-001 or TEC-002 treatment by harnessing the physiological immune response. This approach leverages the patient's own immune system to target tumors, serving as a potent therapeutic strategy to combat cancer. It has the potential to collaboratively target multiple tumor antigens, maximizing its effectiveness.
Our Pipeline
Our approaches promise novel treatments for solid tumors, extending lives and challenge current treatment paradigm for patients who have exhausted treatment options.
Preclinical
Phase 1
Phase 2
Collaborator
TEC-001
+Keytruda
COLORECTAL CANCER
FDA
Meeting
TEC-001
LIVER CANCER
Intermediate stage
FDA
Meeting
TEC-001
+Opdivo
LIVER CANCER
Advanced stage
TEC-001
+Keytruda
LUNG CANCER
TEC-001
+Opdivo
STOMACH CANCER
TEC-001
NEUROENDOCRINE TUMOR
TEC-002
SOLID TUMORS
TEC-003
SOLID TUMORS
Indications
Teclison is preparing to launch its first pipeline product, TATE, for advanced hepatocellular carcinoma (HCC). Currently in phase 2 clinical trials, TATE has shown promising preliminary results in patients with advanced HCC who have not responded to immunotherapy. This result will support advanced HCC as the first indication for TATE. Additionally, phase 2 trials are underway for other cancers, including lung, gastric, colorectal, and neuroendocrine tumors.
Teclison is actively expanding its treatment indications to target a wider range of cancer types with its highly specific, tumor-targeting strategy, providing new hope for patients who have developed resistance to standard treatments.
Targeted Future Indications
